TG Therapeutics

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Earnings data Q1 2023

Earnings data Q2 2023

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics achieved approval of Briumvi, a CD20 antibody for relapsing MS, a needed win following the withdrawal of their only other product. Briumvi has comparable data but a lower cost than other CD20 inhibitors, possibly making it an attractive treatment option.

TG Therapeutics' Briumvi Has Potential For Growth In A Crowded Market

ICER published a report saying TG Therapeutics, Inc.'s briumvi is overpriced. It has said this for other major drugs over the years, with no impact on their bottom lines.

TG Therapeutics: That ICER Report Doesn't Bother Me

NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology (AAN) annual meeting, being held April 22 – 27, 2023 in Boston, Massachusetts. Abstracts are now available online and can be accessed within the AAN annual meeting program at www.aan.com/msa/public/events/index/45. Details of the presentations are outlined below.

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting

TG Therapeutics, Inc. (NASDAQ:TGTX ) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ET Company Participants Jenna Bosco – Investor Relations Michael Weiss – Chairman and Chief Executive Officer Adam Waldman – Chief Commercialization Officer Sean Power – Chief Financial Officer Conference Call Participants Josh Schimmer – Evercore ISI Ed White – H. C. Wainwright Prakhar Agrawal – Cantor Fitzgerald Sahil Kazmi – B.

TG Therapeutics, Inc. (TGTX) Q4 2022 Earnings Call Transcript

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -50% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates

Conference call to be held today, Tuesday, February 28, 2023, at 8:30 AM ET Conference call to be held today, Tuesday, February 28, 2023, at 8:30 AM ET

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results

Conference call to be held Tuesday, February 28, 2023 at 8:30 AM ET Conference call to be held Tuesday, February 28, 2023 at 8:30 AM ET

TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2022 Financial Results and Business Update

NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab-xiiy) in adult patients with relapsing forms of multiple sclerosis (RMS), presented at the 2023 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum. Links to each of the presentations are included below.

TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Growth stock TG Therapeutics has surged 80% after FDA approval for its multiple sclerosis treatment. The post Biotech Growth Stock Boosted By FDA Approval For Multiple Sclerosis Treatment appeared first on Investor's Business Daily.

Biotech Growth Stock Boosted By FDA Approval For Multiple Sclerosis Treatment

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab) in adult patients with relapsing forms of multiple sclerosis (RMS), at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 23 – 25, 2023, in San Diego, California. Abstracts are now available online and can be accessed on the ACTRIMS meeting website at www.forum.actrims.org. Details of the presentations are outlined below.

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

It's been a while since the Marketbeat team flagged a hot stock that had already logged a 300% rally but looked like it was going to go higher. But the New York-headquartered TG Therapeutics Inc (NASDAQ: TGTX) is worth every word.

TG Therapeutics Stock 300% Rally Has Legs Yet

After a year of churn and doldrums, TG Therapeutics, Inc. finally got approval for, and launched, briumvi or ublituximab in RRMS. I am trying to decide what to do with my TG Therapeutics shares, now that I have just broken even after doubling down twice.

TG Therapeutics: Strategy After Briumvi Launch

NEW YORK, Jan. 26, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the commercial launch of BRIUMVI™ (ublituximab-xiiy), for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis

Wilmington, Delaware--(Newsfile Corp. - January 23, 2023) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of TG Therapeutics, Inc. (NASDAQ: TGTX) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-tg-therapeutics-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TG Therapeutics, Inc.

TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

TG Therapeutics (TGTX) Soars 8.7%: Is Further Upside Left in the Stock?

TG Therapeutics (TGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

TG Therapeutics (TGTX) Upgraded to Buy: What Does It Mean for the Stock?

Presentation scheduled for Monday, January 9, 2023 at 9:45 AM PT Presentation scheduled for Monday, January 9, 2023 at 9:45 AM PT

TG Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

TG Therapeutics, Inc. is set to launch Briumvi with an experienced in-house team. There are several factors conducive to launch success. Nevertheless, uncertainty remains.

TG Therapeutics: Ramifications Of Briumvi Approval

Boeing

Caterpillar

Celsius Holdings

Clearfield

Vita Coco

Chevron

DocGo

Enphase Energy

JPMorgan Chase & Co

McDonald's

Merck

Noble Corp PLC

Northern Oil and Gas

Nuvalent

Permian Basin Royalty Trust

Pinduoduo Inc - ADR

Tidewater

Mammoth Energy Services

Visa

Vipshop Hlds

Viridian Therapeutics

Verizon

Wave Life Sciences

Two new Breakout Stocks for Week 1 with better than 10% short-term upside potential and two Dow 30 Picks. Average cumulative returns for 2022 reached +142.69% YTD. The streak of weekly picks gaining over 10% in less than a week of trading days has reached 235 out of 293 trading weeks (80.4%) not counting multiple gainers.

MDA Breakout Stocks Week 1 - January 2023: High-Frequency Gainers To Give You An Edge

The company scored a giant victory on the regulatory front.

Why TG Therapeutics Stock Was a Solid Winner This Week

The FDA approves TG Therapeutics' (TGTX) Briumvi (ublituximab-xiiy) for treating relapsing forms of multiple sclerosis. The company plans to launch the drug in the first quarter of 2023.

TG Therapeutics (TGTX) Gets FDA Nod for Multiple Sclerosis Drug

TG Therapeutics Inc TGTX shares are trading higher by 9.34% to $9.25 Thursday morning. The company on Wednesday revealed FDA approval of ublituximab.

What's Going On With TG Therapeutics Shares - TG Therapeutics (NASDAQ:TGTX)

Pfizer

The stock market lost ground as economic worries persist.

Pfizer Makes Progress, but This Biotech Was Wednesday's Big Winner

BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with relapsing forms of multiple sclerosis that can be administered in a one-hour infusion twice-a-year following the starting dose

TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)

TG Therapeutics is approaching its Prescription Drug User Fee Act (PDUFA) goal date of December 28, 2022, for ublituximab for the treatment of relapsing forms of multiple sclerosis (RMS). It appears that TG will launch ublituximab under the trade name "BRIUMVI".

News for TG Therapeutics Stock (TGTX)